Page last updated: 2024-11-06

1,2,4-triazole-3-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2,4-triazole-3-carboxamide : A member of the class of triazoles that is 1H-1,2,4-triazole substituted by an aminocarbonyl group at position 3. It is the major catabolite and aglycon of ribavirin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65125
CHEBI ID180482
SCHEMBL ID381885
MeSH IDM0069121

Synonyms (46)

Synonym
AC-797
CHEBI:180482
NCIOPEN2_000872 ,
1h-1,2,4-triazole-3-carboxamide
nsc-80860
nsc80860
icn 1253
3641-08-5
STK007228
T2402
1,2,4-triazole-3-carboxamide
1h-1,2,4-triazole-5-carboxamide
zewjfunfeabpgl-uhfffaoysa-
2h-1,2,4-triazole-3-carboxamide
inchi=1/c3h4n4o/c4-2(8)3-5-1-6-7-3/h1h,(h2,4,8)(h,5,6,7)
c405on563a ,
unii-c405on563a
nsc 80860
A823234
1h-1,2,4-triazole-5-carboxamide;1h-1,2,4-triazole-3-carboxamide
AKOS016001784
AKOS005375701
BP-20317
FT-0601192
PS-3438
AKOS017269537
s-triazole-3-carboxamide
ribavirin impurity d [ep impurity]
SCHEMBL381885
ZEWJFUNFEABPGL-UHFFFAOYSA-N
1, 2, 4-triazole-3-carboxamide
1,2,4-triazole- 3-carboxamide
1,2,4-triazole-3-formamide
BS-3499
DTXSID50189935
mfcd15142764
ribavirin imp. d (ep); ribavirin usp related compound d; ribavirin usp rc d; 1h-1,2,4-triazole-3-carboxamide; ribavirin related compound d; ribavirin impurity d
1h-[1,2,4]triazole-3-carboxamide
676456-95-4
F14916
CS-W021700
AMY38327
Q27275157
n-des-1-beta-d-ribofuranosyl ribavirin
EN300-83457
4h-1,2,4-triazole-3-carboxamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
primary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Drug ADME6387
Ribavirin ADME916

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's2 (22.22)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.12 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]